Suppression of innate immunity (natural killer cell/interferon-γ) in the advanced stages of liver fibrosis in mice

Hepatology

Volumn 53, Issue 4, 2011, Pages 1342-1351

  Jeong, Won Il ^a,d   Park, Ogyi ^d   Suh, Yang Gun ^a   Byun, Jin Seok ^a   Park, So Young ^a   Choi, Earl ^a   Kim, Ja Kyung ^b   Ko, Hyojin ^c   Wang, Hua ^d   Miller, Andrew M ^d   Gao, Bin ^d  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Gwangju Institute of Science and Technology (GIST)   (South Korea)

^d NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON TETRACHLORIDE; GAMMA INTERFERON; POLYINOSINIC POLYCYTIDYLIC ACID; RETINOIC ACID INDUCIBLE PROTEIN I; RETINOL; SUPPRESSOR OF CYTOKINE SIGNALING 1; TRANSFORMING GROWTH FACTOR BETA; SOCS1 PROTEIN, MOUSE; SUPPRESSOR OF CYTOKINE SIGNALING;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL FUNCTION; CELL KILLING; CELL PROLIFERATION; CELL THERAPY; COCULTURE; CONTROLLED STUDY; CYTOTOXICITY; DISEASE SEVERITY; ENZYME INHIBITION; GENE; IN VITRO STUDY; INNATE IMMUNITY; LIVER FIBROSIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STELLATE CELL; ANIMAL; BIOSYNTHESIS; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; INTOXICATION; LIVER CIRRHOSIS; METABOLISM;

ANIMALS; CARBON TETRACHLORIDE POISONING; HEPATIC STELLATE CELLS; IMMUNITY, INNATE; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LIVER CIRRHOSIS; MICE; POLY I-C; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TRANSFORMING GROWTH FACTOR BETA; VITAMIN A;

EID: 79953752559     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24190     Document Type: Article

References (27)

1. Gao B, Jeong WI, Tian Z. Liver: an organ with predominant innate immunity. HEPATOLOGY 2008; 47 729-736.
2. Notas G, Kisseleva T, Brenner D. NK and NKT cells in liver injury and fibrosis. Clin Immunol 2009; 130: 16-26.
3. Muhanna N, Abu Tair L, Doron S, Amer J, Azzeh M, Mahamid M, et al. Amelioration of hepatic fibrosis by NK cell activation. Gut 2010; 60: 90-98.
4. Radaeva S, Sun R, Jaruga B, Nguyen VT, Tian Z, Gao B. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology 2006; 130: 435-452.
5. Melhem A, Muhanna N, Bishara A, Alvarez CE, Ilan Y, Bishara T, et al. Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. J Hepatol 2006; 45: 60-71.
6. Jeong WI, Park O, Radaeva S, Gao B. STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity. HEPATOLOGY 2006; 44: 1441-1451.
7. Jeong WI, Park O, Gao B. Abrogation of the antifibrotic effects of natural killer cells/interferon-gamma contributes to alcohol acceleration of liver fibrosis. Gastroenterology 2008; 134: 248-258.
8. Radaeva S, Wang L, Radaev S, Jeong WI, Park O, Gao B. Retinoic acid signaling sensitizes hepatic stellate cells to NK cell killing via upregulation of NK cell activating ligand RAE1. Am J Physiol Gastrointest Liver Physiol 2007; 293: G809-G816.
9. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134: 1655-1669.
10. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008; 88: 125-172.
11. Baroni GS, D'Ambrosio L, Curto P, Casini A, Mancini R, Jezequel AM, et al. Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis. HEPATOLOGY 1996; 23: 1189-1199.
12. Rockey DC, Chung JJ. Interferon gamma inhibits lipocyte activation and extracellular matrix mRNA expression during experimental liver injury: implications for treatment of hepatic fibrosis. J Investig Med 1994; 42: 660-670.
13. Weng HL, Wang BE, Jia JD, Wu WF, Xian JZ, Mertens PR, et al. Effect of interferon-gamma on hepatic fibrosis in chronic hepatitis B virus infection: a randomized controlled study. Clin Gastroenterol Hepatol 2005; 3: 819-828.
14. Muir AJ, Sylvestre PB, Rockey DC. Interferon gamma-1b for the treatment of fibrosis in chronic hepatitis C infection. J Viral Hepat 2006; 13: 322-328.
15. Pockros PJ, Jeffers L, Afdhal N, Goodman ZD, Nelson D, Gish RG, et al. Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. HEPATOLOGY 2007; 45: 569-578.
16. Brysha M, Zhang JG, Bertolino P, Corbin JE, Alexander WS, Nicola NA, et al. Suppressor of cytokine signaling-1 attenuates the duration of interferon gamma signal transduction in vitro and in vivo. J Biol Chem 2001; 276: 22086-22089.
17. Dasgupta S, Bhattacharya-Chatterjee M, O'Malley BW Jr, Chatterjee SK. Inhibition of NK cell activity through TGF-beta 1 by down-regulation of NKG2D in a murine model of head and neck cancer. J Immunol 2005; 175: 5541-5550.
18. Rockey DC, Maher JJ, Jarnagin WR, Gabbiani G, Friedman SL. Inhibition of rat hepatic lipocyte activation in culture by interferon-gamma. HEPATOLOGY 1992; 16: 776-784.
19. Nakagawa R, Naka T, Tsutsui H, Fujimoto M, Kimura A, Abe T, et al. SOCS-1 participates in negative regulation of LPS responses. Immunity 2002; 17: 677-687.
20. Choi WH, Ji KA, Jeon SB, Yang MS, Kim H, Min KJ, et al. Anti-inflammatory roles of retinoic acid in rat brain astrocytes: suppression of interferon-gamma-induced JAK/STAT phosphorylation. Biochem Biophys Res Commun 2005; 329: 125-131.
21. Yu J, Wei M, Becknell B, Trotta R, Liu S, Boyd Z, et al. Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells. Immunity 2006; 24: 575-590.
22. Iredale JP. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 2007; 117: 539-548.
23. Davey GM, Heath WR, Starr R. SOCS1: a potent and multifaceted regulator of cytokines and cell-mediated inflammation. Tissue Antigens 2006; 67: 1-9.
24. Duester G, Mic FA, Molotkov A. Cytosolic retinoid dehydrogenases govern ubiquitous metabolism of retinol to retinaldehyde followed by tissue-specific metabolism to retinoic acid. Chem Biol Interact 2003; 143-144: 201-210.
25. Napoli JL. Interactions of retinoid binding proteins and enzymes in retinoid metabolism. Biochim Biophys Acta 1999; 1440: 139-162.
26. Natarajan SK, Thomas S, Ramachandran A, Pulimood AB, Balasubramanian KA. Retinoid metabolism during development of liver cirrhosis. Arch Biochem Biophys 2005; 443: 93-100.
27. Hellemans K, Verbuyst P, Quartier E, Schuit F, Rombouts K, Chandraratna RA, et al. Differential modulation of rat hepatic stellate phenotype by natural and synthetic retinoids. HEPATOLOGY 2004; 39: 97-108.